Is visceral adiposity the "enemy within"?

Recently, data from diverse areas of investigation have come together to implicate chronic low-level inflammation as an important pathogenetic factor in atherosclerotic cardiovascular disease (CVD). As recently summarized by Ross,1 studies in cell biology, animal models, clinical research, and epidemiology have been remarkably consistent in validating the early work of Virchow2 and others, suggesting that atherosclerotic lesions are essentially an inflammatory response. In clinical research and epidemiology, 2 inflammation blood markers in particular, fibrinogen and C-reactive protein (CRP), have been used. Many studies have confirmed that these markers predict future cardiovascular events independently of more traditional cardiovascular risk factors, such as plasma lipid levels.3 4 5 Because of this, several investigators have suggested that CRP might prove useful in clinical practice,6 7 whereas others have favored fibrinogen.8 9 Although there are important details to work out before either of these markers enters the clinical domain, this interest provides a clear and compelling imperative for understanding how inflammation integrates into both normal physiology and atherothrombotic pathophysiology. Focusing on CRP, population-based research efforts have revealed that in general, women have slightly higher values than men, blacks have higher values than whites, and those with clinical CVD have higher values than those without10 11 12 13 (M. Cushman, et al, manuscript in preparation). In those without clinical CVD, metabolic variables consistently correlated with CRP include body mass index (BMI), glucose tolerance status/diabetes status, and level of coagulation activation. In addition, depending on the population being studied, other correlates of CRP may include smoking status, plasma lipids (especially HDL cholesterol), hypertension, evidence of chronic infection, and measures of subclinical atherosclerotic disease, such as ankle-brachial blood pressure index (ABI). Whether or not some variables have been identified as significant correlates appears to depend, at least in part, on the …

[1]  P. Sakkinen,et al.  Interleukin-6 exacerbates early atherosclerosis in mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[2]  S. Gregory,et al.  Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin , 1989, Molecular and cellular biology.

[3]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[4]  L. Kuller,et al.  Hormone replacement therapy, inflammation, and hemostasis in elderly women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[5]  T. Strandberg,et al.  Effect of statins on C-reactive protein in patients with coronary artery disease , 1999, The Lancet.

[6]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[7]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[8]  Ridker Pm Novel risk factors and markers for coronary disease. , 2000 .

[9]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[10]  N Rifai,et al.  Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. , 2001, Clinical chemistry.

[11]  D. Loskutoff,et al.  The adipocyte and hemostatic balance in obesity: studies of PAI-1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[12]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[13]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[14]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[15]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[16]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[17]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[18]  J. Després,et al.  Elevated C-Reactive Protein: Another Component of the Atherothrombotic Profile of Abdominal Obesity , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[19]  E. Poehlman,et al.  Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. , 1999, Diabetes.

[20]  R. Puri,et al.  Human Cytokines: Their Role in Disease and Therapy , 1995 .

[21]  Gerardo Heiss,et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.

[22]  E. Poehlman,et al.  Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 48: 2210-2214 , 1999 .

[23]  L. Heilbronn,et al.  Energy Restriction and Weight Loss on Very-Low-Fat Diets Reduce C-Reactive Protein Concentrations in Obese, Healthy Women , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[24]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[25]  R. Tracy,et al.  Inflammation markers and coronary heart disease. , 1999, Current opinion in lipidology.

[26]  R. Tracy,et al.  The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.

[27]  R. Virchow,et al.  Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre , 1861 .

[28]  L. Kuller,et al.  Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[29]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[30]  S. O’Rahilly,et al.  The perils of portliness: causes and consequences of visceral adiposity. , 2000, Diabetes.

[31]  B. Horne,et al.  Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. , 2000, Journal of the American College of Cardiology.

[32]  C. Esmon,et al.  Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C , 1991, Thrombosis and Haemostasis.

[33]  J. Kolls,et al.  An in Vivo Model for Elucidation of the Mechanism of Tumor Necrosis Factor-α (TNF-α)-Induced Insulin Resistance: Evidence for Differential Regulation of Insulin Signaling by TNF-α. , 1998, Endocrinology.

[34]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[35]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[36]  R. Tracy Inflammation in cardiovascular disease: cart, horse, or both? , 1998, Circulation.

[37]  G. Montalescot,et al.  Fibrinogen as a risk factor for coronary heart disease. , 1998, European heart journal.

[38]  J. Polak,et al.  Association between physical activity and markers of inflammation in a healthy elderly population. , 2001, American journal of epidemiology.

[39]  P. Ridker,et al.  Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001, Circulation.

[40]  J. Verheijen,et al.  The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. , 1985, Scandinavian journal of clinical and laboratory investigation.

[41]  J. Yudkin Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? , 1999, Diabetes Care.